Delving into the Latest Updates on Prilocaine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-(Propylamino)-o-propionotoluidide, 2-Methyl-alpha-propylaminopropionanilide, N-(2-Methylphenyl)-2-(propylamino)propanamide

+ [14]

Target

SCNA x VDCCs

Mechanism

SCNA modulators(Sodium channel alpha subunit modulators), VDCCs modulators(Voltage-gated calcium channel modulators)

Therapeutic Areas

Urogenital Diseases

Active Indication

Hyperemesis Gravidarum

Inactive Indication

Anesthesia

Originator Organization

AstraZeneca PLC

Active Organization

Hubei Jumpcan Pharmaceutical Co., Ltd.

Inactive Organization

AstraZeneca LP

Drug Highest PhaseApproved

First Approval Date

US (18 Nov 1965),

Anesthesia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC13H21ClN2O

InChIKeyBJPJNTKRKALCPP-UHFFFAOYSA-N

CAS Registry1786-81-8

View All Structures (2)

The goal of this randomised trial is to use a short acting local anaesthetic drug (hyperbaric prilocaine 2%) which is beneficial in short operations which are performed as a day case surgery.
in this study the investigators will use 3 different doses of prilocaine 2% (40,50 or 60 mg ) intrathecal (in spinal anaesthesia) in participants undergoing arthroscopy on the knee.
the primary outcome is to compare time to micturate (go to the bathroom) between the three groups .
the secondary outcomes are:
* time to recovery of the motor and sensory block
* time to discharge from post anesthesia care unit
* any complications ; itching, lowered blood pressure, nausea and vomiting.

Start Date30 Nov 2024

Sponsor / Collaborator

Cairo University

NCT06680167

/ Active, not recruitingEarly Phase 1IIT

A Comparative Study Between Hyperbaric Prilocaine 2% Versus Hyperbaric Bupivacaine 0.5% For Intrathecal Anesthesia in Caesarean Section

Comparison between effects of hyperbaric bupivacaine 0.5% vs Hyperbaric prilocaine 2% in spinal anesthesia of women undergoing elective caesarean section such as onset time of sensory and motor block, duration of sensory and motor block, effects of maternal hemodynamics and expected side effects .

Start Date09 Oct 2024

Sponsor / Collaborator

Sohag University

CTRI/2024/09/073516

/ RecruitingPhase 4IIT

Efficacy & safety of topical Lidocaine and Prilocaine gel for arteriovenous fistula cannulation pain in hemodialysis patients A Crossover Randomized Control Trial - NIL

Start Date24 Sep 2024

Sponsor / Collaborator

Manipal college of Medical Sciences

100 Clinical Results associated with Prilocaine Hydrochloride

Login to view more data

100 Translational Medicine associated with Prilocaine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Prilocaine Hydrochloride

Login to view more data

1,907

Literatures (Medical) associated with Prilocaine Hydrochloride

01 Feb 2025·World Neurosurgery

Comparison of Different Local Anesthetics in Cervical Facet Medial Branch Blockade

Article

Author: Meço, Başak Ceyda ; Özgencil, Güngör Enver ; Başarı, Ahmet ; Asiller, Özgün Ömer ; Ünal, Hanzade Aybüke

OBJECTIVECervical medial branch blocks (CMBBs) are frequently used for the treatment of facet arthropathy. The present study compares the effectiveness of lidocaine and prilocaine in CMBB procedures.METHODSPatients with facet arthropathy scheduled for CMBB were randomly divided into 2 groups who were administered a combination of 2 mg dexamethasone and either 1% lidocaine or 1% prilocaine with a total volume of 1 mL per level. All patients were assessed prior to the procedure (baseline), and at 1 hour, 1 week, and 1 month after the procedure using the Numeric Rating Scale-11 (NRS-11), Neck Disability Index (NDI), and patient satisfaction was evaluated at 1 hour, 1 week, and 1 month after the procedure.RESULTSA total of 97 patients were included in the study (n = 49 in the lidocaine group and n = 48 in the prilocaine group). A significant decrease was noted in the NRS-11 and NDI scores recorded during all follow-up assessments in both groups (P < 0.001), while the NRS-11, NDI scores, and patient satisfaction did not statistically differ between groups at 1 hour, 1 week, and 1 month following the procedure (P ˃ 0.05).CONCLUSIONSCMMB achieved with either lidocaine or prilocaine decreased the recorded pain severity and disability scores to a similar degree. The selection of either lidocaine or prilocaine for CMBB is thus at the clinician's discretion.

01 Jan 2025·Regional Anesthesia & Pain Medicine

Crystallization of mixtures of local anesthetics with and without select adjuvants: a semiquantitative light microscopy analysis

Article

Author: Stundner, Ottokar ; Fiegl, Heidi ; Hoerner, Elisabeth ; Gasteiger, Lukas ; Seisl, Anna

IntroductionInjecting mixtures of local anesthetics with or without adjuvants is a common practise in regional and particularly obstetric anesthesia to decrease block onset time and/or augment epidural analgesia for cesarean section. While evidence on the efficacy of this practise is equivocal, little is known about its safety in terms of the pharmacologic compatibility of local anesthetics.MethodsWe assessed the grade of crystallization in individual mixtures of seven local anesthetics (bupivacaine, ropivacaine, lidocaine, procaine, chloroprocaine, mepivacaine, prilocaine) with or without four adjuvants (sodium bicarbonate, dexamethasone, clonidine, fentanyl) using a semiquantitative light microscopy scale (ranging from 0 to 5), repeatedly for up to 60 min and performed correlation analysis between grade of crystallization and initial solution pH.ResultsOf the 50 mixtures tested, 26 showed grades of crystallization ≥4 at admixture and 41 showed grades of crystallization ≥4 after 60 min. The addition of adjuvants to local anesthetic mixtures did not substantially change the grades of crystallization. Bupivacaine has a slightly lower precipitation tendency, compared with ropivacaine. A moderate relationship was found between initial pH and grade of crystallization after 15 min for the adjuvant mixtures (R=0.33, p=0.04), but not at other time points.DiscussionThe preparation of local anesthetic (±adjuvant) mixtures leads to high grades of crystallization, which increase over 60 min and appear independent of solution pH. The risk of mixing medications with unknown physical or chemical compatibility profiles in regional anesthesia should be critically appraised and its clinical significance elucidated in future translational research.

01 Dec 2024·Journal of Cosmetic Dermatology

Evaluating the efficacy of local anesthetic techniques during scalp microneedling

Article

Author: Smoczok, Michał ; Bergler‐Czop, Beata ; Leonik, Szymon

AbstractIntroductionAn increasing interest in minimally invasive procedures hassled to a demand for an effective local anesthetic algorithm. The scalp presents a challenge in achieving effective anesthesia due to the presence of hair shafts. This study aims to evaluate the efficacy of different methods during a microneedling procedure, including 25 mg lidocaine and 25 mg prilocaine cream, skin spray with 10% lidocaine, and cold gel compresses.Materials and MethodsSixty‐two men aged between 20 and 50 years underwent three microneedling treatments, each using a different method of anesthesia. The treatment area was divided into two equal parts, with one part exposed to a specific anesthetic method. Patients were asked to rate their pain on a 0–10 verbal analog scale. An attempt was made to objectify the results using algometry.ResultsA negative correlation was observed between the algometry results and the VAS score after the application of the cream and cold compresses.DiscussionWhen choosing monotherapy, it is recommended to use cold gel compresses for scalp microneedling after considering the advantages and disadvantages of different methods.

2

News (Medical) associated with Prilocaine Hydrochloride

07 Nov 2023

·www.prnewswire.com

Advanced Anesthesia Devices and Ambulatory Surgical Centers Propel Growth in the US Anesthesia Market

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market (by segment, Type, Drug Product, & Device Product): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market is poised for significant growth, with a projected value of US$6.83 billion in 2023, experiencing a robust CAGR of 6.78% during the forecasted period. Anesthesia, the use of drugs to alleviate pain during medical procedures, is essential in the healthcare industry and is administered through various means such as injection, inhalation, topical application, and more. Market Segmentation The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices. Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region. Types and Products In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia. The General anesthesia drug segment dominates the market, followed by local anesthesia drugs. The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment. When considering device products, the market is segmented into advanced, basic, and integrated anesthesia devices. The advanced segment holds the largest share in the market, followed by integrated anesthesia devices. Ongoing advancements in anesthesia monitoring devices and the demand for improved monitoring contribute to the growth of the advanced anesthesia monitoring devices market. The market is further categorized by drug product into Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine, and other local anesthetics. Lidocaine anesthesia drugs have the highest market share, followed by Bupivacaine and Ropivacaine. The market is anticipated to grow due to increasing patient populations and a rise in medical and surgical procedures. Key Drivers and Challenges Driver: Increase in Monitored Anesthesia Use The adoption of Monitored Anesthesia Care (MAC) is on the rise. MAC involves specific anesthesia services for procedures performed under local anesthesia with sedation and analgesia, allowing patients to maintain consciousness. Patients are opting for monitored anesthesia to ensure satisfaction during surgeries, leading to increased usage of anesthesia equipment and drugs. Challenge: Side Effects of Anesthesia While anesthesia is generally administered by anesthesiologists, it can sometimes lead to side effects, including nausea, headache, vomiting, and shivering, among others. General anesthetics can affect the central nervous system, causing drowsiness and coordination problems. These side effects can deter some patients and impact the growth of the anesthesiology market. Trend: Growth of Ambulatory Surgical Centers (ASC) The establishment of ambulatory surgical centers (ASCs) is escalating due to an aging population and the prevalence of chronic diseases. ASCs offer improved reimbursement and a reduced risk of healthcare-associated infections, attracting more patients. This growth in ASCs is driving the demand for anesthesia drugs and devices. COVID-19 Analysis The COVID-19 pandemic led to increased utilization of intensive care unit (ICU) ventilators and anesthesia machines for longer-term ventilation. Anesthesia drugs were used during longer-term ventilation with anesthesia machines. Initially, anesthesia drug demand decreased in 2020 due to postponed or canceled surgeries. However, as elective surgeries resumed, anesthesia drug consumption increased. Key Players The US anesthesia drugs and devices market is competitive and features several major players, including Baxter International Inc., Envision Healthcare Corporation (KKR & Co. Inc.), Becton, Dickinson and Company, TeamHealth (Blackstone), Teleflex Incorporated, Dragerwerk AG & Co. KGaA, B. Braun Avitum AG (Braun), 3M Company, Abbvie Inc., AstraZeneca Plc, Abbott Laboratories, ICU Medical, Inc., SunMed LLC, and General Electric Company. Top Impacting Factors Growth Drivers Rising Geriatric Population Growing Healthcare Expenditure Increase in Monitored Anesthesia Use Increase In Number Of Approval For Anesthesia Drugs Challenges Side Effects of Anesthesia Lack of Skilled Anesthesiologist Trends Escalating Establishment of Ambulatory Surgical Centers (ASC) Technological Enhancement of Anesthesia Devices For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

18 Nov 2022

·www.prnewswire.com

US Anesthesia Drugs and Devices Market to Reach $8.88 Billion by 2027

DUBLIN, Nov. 18, 2022 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market: Analysis By segment, By Type, By Drug product, By Device Product, Size And Trends With Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion. The market value is predicted to reach US$8.88 billion by 2027. Anesthesia is the use of medicines to prevent pain during surgery and other procedures. They may be given by injection, inhalation, topical lotion, spray, eye drops, or skin patch. Anesthesia can cause one to have a loss of feeling or awareness. The market is expected to grow at a CAGR of 6.80% during the forecast period of 2022-2027. Due to increasing number of surgeries, aging population with increasing chronic conditions, and advancements in anesthesia technologies, the market for anesthesia drugs and devices would grow in the years to come. Market Segmentation Analysis: By Segment: The report provides the bifurcation of the market into two categories based on the segment: anesthesia drugs and anesthesia devices. In 2021, anesthesia drugs segment held a major share of more than 55% in the market. On the other hand, the anesthesia devices segment is expected to grow at a significant CAGR in the forthcoming years owing to the rising healthcare expenditure in the region. By Type: On the basis of type, the US anesthesia drugs market is divided into three types namely general, local and other anesthesia. In 2021, general anesthesia drug segment held a major share of more than 39% in the market. This was being followed by local anesthesia drugs. R&D activities in the pharmaceutical industry to formulate novel anesthesia drug is expected to provide remunerative opportunities for expansion of the US other anesthesia drugs market during forecast period. By Device Product: The report provides the bifurcation of the market into three segments based on the device product: advanced, basic and integrated. In 2021, advanced segment held a major share of 62% in the market. This was being followed by integrated anesthesia device. The constant development in the field of the anesthesia monitoring devices and high demand for the better monitoring devices are also anticipated to push the growth in the US advanced anesthesia monitoring devices market. By Drug Product: The report provides the bifurcation of the market into seven segments based on the drug product: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine and Other Local Anesthetics. In 2021, Lidocaine anesthesia drug segment held a major share of 32% in the market. This was being followed by Bupivacaine, Ropivacaine. The market is anticipated to propel during forecasted years owing to the expanding patient population and the rise in medical and surgical procedures. Market Dynamics: Growth Drivers: One of the most important factors impacting the US anesthesia drugs and devices market is rising geriatric population. Steady growth in aging population raised the incidence of the chronic condition over the past decade. This had caused increasing number of surgical procedures of elderly patients. Additionally, benefits such as advances in surgery and anesthesia can improve function and quality of life for older patients also supported market growth. Thus, the positive acceleration in aging population consequently supported the growth of the anesthesia drugs and devices market in the US. Furthermore, the market has been growing over the past few years, due to factors such as growing healthcare expenditure, increase in monitored anesthesia use, increase in number of approval for anesthesia drugs and many other factors. Challenges: However, the market has been confronted with some challenges specifically, lack of skilled anesthesiologist, etc. - Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as the escalating establishment of ambulatory surgical centers (ASC), technological enhancement of anesthesia devices, etc. Technology upgradation such as Closed loop TIVA and Ultrasound-Guided Regional Anesthesia (UGRA) are expected to propel the US drug and devices market during forecasted years. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Impact of COVID-19 5. Market Dynamics 6. Competitive Landscape 7. Company Profiles Companies Mentioned KKR & Co. Inc. (Envision Healthcare Corporation) Baxter International Inc. Blackstone (TeamHealth) Becton, Dickinson and Company Braun (B. Braun Avitum AG) 3M Company Abbvie Inc. Teleflex Incorporated Dragerwerk AG & Co. KGaA AstraZeneca Plc Abbott Laboratories General Electric Company ICU Medical, Inc SunMed LLC For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Prilocaine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01243	Prilocaine Hydrochloride	N01BB04	DB00750

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hyperemesis Gravidarum	CN	Hubei Jumpcan Pharmaceutical Co., Ltd.	13 Feb 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AUA2024	Not Applicable	Premature Ejaculation	-	Dapoxetine 30 mg+mirodenafil 50 mg	(nlorlzskeu) = nnoiugboao ftlzwgeiqe (vskgfdpsab, 23.0 - 400.0)	Positive	01 May 2024
				OLNP-05	(nlorlzskeu) = uoogfcpzvx ftlzwgeiqe (vskgfdpsab, 140.0 - 410.0)
NCT02973048 (not provided, CTgov)	Phase 3	Pain \| Hypotension	40	Hyperbaric bupivacaine (Hyperbaric Bupivacaine)	ygrfrxmrvt(fcskwkqqhm) = ozufpuqtlv knlxlpeecd (shceshnaiy, zxgjjmbeyb - dpacduaogq) View more	-	02 Jul 2020
				Hyperbaric prilocaine (Hyperbaric Prilocaine)	ygrfrxmrvt(fcskwkqqhm) = erkkzqadjp knlxlpeecd (shceshnaiy, epvutftepk - ntqobtujeg) View more
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	hbkcbdqnkt(omjvtfpvzx) = yueduresjg ybazpuzrzk (srjlpdoyel, xtzufjxhrj - aoshewpbrm) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	hbkcbdqnkt(omjvtfpvzx) = mgjkrhiwpq ybazpuzrzk (srjlpdoyel, cmfpaqpteu - xbteoxkesy) View more
NCT05834647 (Pubmed \| Local Reg Anesth)	Phase 4	Anesthesia	-	Prilocaine hydrochloride 2% hyperbaric solution	mmbwtmrvtk(vxqhcrtgwl) = eqebhmqqry avradgrcah (djadymaqyu ) View more	-	01 Jan 2017
NCT00556478 (CTgov)	Phase 2/3	Premature Ejaculation	256	prilocaine+PSD502, contains a mixture of lidocaine (Double-Blind Active)	erzdqugbbi(dfzxtdxuoy) = lycpklqntr fgopntdkoj (fwmoixoygo, kiiffqctsy - iyippuzsne) View more	-	26 Sep 2016
				Placebo (Double-Blind Placebo)	erzdqugbbi(dfzxtdxuoy) = msdkqxnlfb fgopntdkoj (fwmoixoygo, uagmypmyue - bbxepopvec) View more
NCT02336958 (CTgov)	Not Applicable	Carotid Stenosis	40	intermediate cervical plexus block ropivacaine+jugular infiltration prilocaine (Ropivacaine)	rxdnajaywq(ivuuixpbnj) = zwzrkehjxl rbdnvtjqtk (zhaetxywbt, yugbjfixcv - ffkezzpjpm) View more	-	23 Mar 2015
				pericarotidal infiltration (placebo comparator) saline+intermediate cervical plexus block ropivacaine+jugular infiltration prilocaine (Saline)	rxdnajaywq(ivuuixpbnj) = hwpgsupidb rbdnvtjqtk (zhaetxywbt, duqosnizdd - mqgmfsllnn) View more
NCT01643616 (CTgov)	Not Applicable	-	250	ultrasound guidance+Prilocaine 1%+Ropivacaine 0.75%+midazolam (Group US)	fptawubqsj(npqqobiosn) = cpggzwiilo nuqpzommgq (pngjyhvqpg, elbxrdpyvr - fvdhwzegyk) View more	-	01 Nov 2013
				nerve stimulation technique+Prilocaine 1%+Ropivacaine 0.75%+midazolam (Group NS)	fptawubqsj(npqqobiosn) = aginlmdwqw nuqpzommgq (pngjyhvqpg, ptpnbohqwc - pkfmqmilkj) View more
NCT01309360 (CTgov)	Phase 4	-	120	prilocaine 1%+midazolam (Group A : 40ml Prilocaine 1%)	axaaqdyojw(latatzlcpj) = dftrqsugke mvmxsqzigw (ydcyjedwee, cmmxpgovob - bsjcbmxozt) View more	-	27 Jun 2011
				prilocaine 1%+midazolam (Group B : 30ml Prilocaine 1%)	axaaqdyojw(latatzlcpj) = nqjktxofjc mvmxsqzigw (ydcyjedwee, eoogsqoyuy - virolapbor) View more